


Oncology
2024-04-10

Recent interest in Interleukin-12 (IL-12) as a therapeutic target led to the development of the BALB/c-hIL12RB1/hIL12RB2 humanized mouse model, preserving intracellular signaling and effectively expressing human IL12RB1 and IL12RB2. This model demonstrates enhanced activation of cytotoxic lymphocytes, natural killer cells, and interferon production, validating IL-12 as a potential anti-tumor drug target. Successful validation of the model suggests its utility in understanding IL-12's therapeutic mechanisms and developing novel anti-tumor treatments.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
